Skip to main content

Table 1 Baseline and clinical characteristics

From: Cumulative lactate and hospital mortality in ICU patients

Characteristic

All

Survivors

Nonsurvivors

p valuea

 

n = 2,251

n = 1846

n = 405

 

Age (yr)

66 (12–98)

69 (57–76)

75 (67–81)

 

Sex M : F (%)

61 : 39

61 : 39

60 : 40

 

SAPS-II

38 (20–113)

33 (24–43)

51 (41–65)

<0.001*

SOFA

    

APACHE II

17 (10–54)

15 (11–19)

23 (17–28)

<0.001*

Admission source (%)

   

<0.01#*

 Emergency

20.2

20.4

19.3

 

 Surgical / OR

43.7

47.3

27.0

 

 Medical

27.2

23.7

43.1

 

 CCU

8.0

7.5

10.1

 

 Other

0.9

1.1

0.5

 

Diagnosis (%)

   

<0.01#*

 Vascular surgery

16.0

17.2

10.4

 

 Abdominal surgery

22.4

23.5

17.2

 

 Other surgery

9.8

10.9

4.9

 

 Heart failure

14.8

12.3

26.4

 

 Respiratory failure

11.8

11.5

13.4

 

 GI bleeding

3.8

4.3

1.5

 

 Neurological

4.5

4.6

2.7

 

 Other

3.7

3.9

4.2

 

 Sepsis

13.1

11.8

19.2

 

Vasoactive agent (%)

33

28

57

<0.001*

LOS ICU (days)

2 (1–5)

2 (1–5)

3 (1–8)

<0.001*

LOS HOSP (days)

14 (7–27)

15 (9–28)

6 (2–16)

<0.001*

In-hospital mortality (%)

18

   
  1. Data are presented as numbers and median (interquartile range). AUC, area under the curve; SAPS-II, simplified acute physiology score; APACHE II, acute physiology, age and chronic health evaluation; OR, operating room; CCU, cardiac care unit; GI, gastrointestinal; vasoactive agent: noradrenaline, dopamine, dobutamine, phosphodiesterase inhibitor; LOS ICU, length of stay at intensive care; LOS HOSP, length of stay at hospital; aSurvivors vs. nonsurvivors; bAll normal lactate (AUC = 0) vs. all elevated lactate (AUC > 0); *Statistically significant difference. Statistics by Chi-square tests# and Wilcoxon rank-sum tests.